Valero G, Peters J, Jorgensen J H, Graybill J R
Department of Infectious Diseases, University of Texas Health Science Center at San Antonio 78284-7870, USA.
Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1555-7. doi: 10.1164/ajrccm.152.5.7582293.
During a period of 11 yr (1983-1993) 137 clinical isolates of Mycobacterium simiae obtained from 75 patients were identified in a University hospital in San Antonio, Texas. One hundred twenty-eight isolates (93%) were from a pulmonary source, four (3%) from blood, and five from other sites including skin, urine, lymph node, bone marrow, and brain. Of 62 evaluable patients, six (10%) had definite infection, nine (14%) had probable disease, and 48 (76%) were thought to be colonized. During the last 2 yr of the study (1992 and 1993), M. simiae became the second most frequently isolated nontuberculous mycobacterium at this institution surpassed only by Mycobacterium avium complex. There are limited data about effective treatment for this multidrug-resistant organism. New macrolides, quinolones, ethambutol, clofazimine, and aminoglycosides are promising therapeutic agents.
在11年期间（1983 - 1993年），从德克萨斯州圣安东尼奥市一家大学医院的75名患者中分离出137株猿分枝杆菌临床菌株。其中128株（93%）来自肺部，4株（3%）来自血液，5株来自其他部位，包括皮肤、尿液、淋巴结、骨髓和大脑。在62例可评估的患者中，6例（10%）有明确感染，9例（14%）可能患病，48例（76%）被认为是定植。在研究的最后两年（1992年和1993年），猿分枝杆菌成为该机构第二常见的非结核分枝杆菌，仅次于鸟分枝杆菌复合群。关于这种多重耐药菌的有效治疗数据有限。新型大环内酯类、喹诺酮类、乙胺丁醇、氯法齐明和氨基糖苷类是有前景的治疗药物。
